Evoq Technologies Corp.

Reshaping Retinal Diagnostics Evoq Technologies is transforming vision care with wearable, accessible diagnostics that detect retinal and neurological diseases earlier than ever—before vision is lost. Our Mission: To make early detection scalable and functional. We deliver mobile, cloud-connected devices that outperform imaging by testing function at the earliest stage of disease—empowering care in clinics or at home. Breakthrough Product Line 🔹 Twilight™ – Class I wearable for self-administered dark adaptation testing to detect nyctalopia, a key early sign of AMD. 🔹 SmartERG® – Smartphone-based full-field ERG/VEP for inherited retinal diseases, DR, and veterinary use. 🔹 Gleam™ – Full-field threshold test in development for late-stage inherited retinal disease. 🔹 DAP – A 5x5 ft. dark enclosure for standardized clinic and research testing. 🔹 SightGard™ – A HIPAA-compliant, AI-ready cloud for longitudinal retinal data. Why We're Different Function over form – Detects dysfunction before structural changes appear. Wearable & smart – Portable, easy-to-use tools that fit standard workflows. Diagnostics-as-a-Service – Subscription-based model breaks cost barriers. Data-driven – Over 50,000 scans expected by 2026, fueling AI and clinical research. The Need • 50%+ of early retinal diseases missed by imaging • 19M+ Americans with AMD; doubling by 2050 • 1 in 8 seniors experiences night vision loss • Early detection lowers costs & improves outcomes 🤝 Join us—researchers, clinicians, and investors—as we shape the future of diagnostics. #RetinalHealth #earlydetection

• Employees 8